US stocks closed in the red Tuesday as investors digested a wave of corporate earnings and economic data, while bracing for ...

Sarepta Therapeutics’ stock was soaring Tuesday after the FDA recommended lifting the pause on the company’s Duchenne ...

Shares of Sarepta Therapeutics surged Tuesday morning after the company said it had been informed by the Food and Drug Administration that it could resume shipping a drug it paused sales of last week.

Vor Biopharma extended its winning streak to a fourth consecutive day on Monday, jumping 10 percent to close at $2.42 apiece ...

US stocks moved higher on Tuesday, eyeing a bid for more records as investors combed through a fresh rush of corporate ...

The lack of a trade agreement between the United States and China could lead to a significant drop in Chinese exports to the ...

Analysts’ view on the stock has dramatically changed over the past few months. Currently, only 21% of the 29 analysts ...

"This was primarily driven by 18% growth seen from the oncology portfolio, which has done well as a result of key drugs such ...

Shares of life sciences company Revvity (NYSE:RVTY) fell 7.6% in the afternoon session after the company lowered its ...

Sarepta Therapeutics (SRPT) shares dropped sharply on Monday following news that the FDA is investigating a patient death potentially connected to its gene therapy, Elevidys.

Sarepta Therapeutics now trades at book value with strong cash and cost-cutting plans, while ELEVIDYS may regain broader use.